Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer vaccine NY-ESO-1 - Therion Biologics

Drug Profile

Cancer vaccine NY-ESO-1 - Therion Biologics

Alternative Names: Recombinant vaccinia/fowlpox NY-ESO-1 cancer vaccine - Therion Biologics

Latest Information Update: 05 Jan 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therion Biologics
  • Developer Ludwig Institute for Cancer Research; Therion Biologics
  • Class Cancer vaccines; Peptide vaccines; Peptides; Saponins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Nov 2006 Clinical data have been added to the adverse events and Cancer pharmacodynamics as well as therapeutic trials sections
  • 04 Jul 2003 Data presented at the 39th Annual Meeting if the American Society of Clinical Oncology (ASCO-2003) have been added to the pharmacodynamics and Cancer therapeutic trials section
  • 19 Sep 2002 Therion Biologics has entered into a non-exclusive licensing agreement with Boehringer Ingelheim Pharmaceuticals for ICAM-1
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top